Answers are grounded in this paper and cite their sources.
OBJECTIVE: The management of pancreatic duct disruption is complex and depends on several factors including the cause, morphology, and degree of disruption. ERCP can show duct disruption in as many as 75% of patients but is invasive and cannot detect disruption beyond an obstruction. We studied the role of secretin MR cholangiopancreatography in patients with suspected pancreatic duct disruption. CONCLUSION: Secretin MR cholangiopancreatography is a safe, noninvasive test that can provide additional useful information about duct integrity and facilitate management.
No takes yet. Share an insight, caveat, or question.
Gillams et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: